Lineage buys a Huntington’s disease cell therapy with six patients treated. Can HUNT1 overcome the next hurdle?
Lineage acquires NeuroAirmid and its HUNT1 Huntington's disease cell therapy. See how trial evidence, manufacturing and deal milestones shape its future.